Introduction
============

Incidence and prevalence of opioid abuse
----------------------------------------

The rate of both illicit and prescription drug misuse and abuse has steadily risen throughout the United States. According to the 2009 National Survey on Drug Use and Health report, illicit drug use (eg, cocaine and heroin) grew from 8.3% in 2002 to 8.9% in 2010 in persons aged 12 years or older.[@b1-sar-2-219] In addition, the efforts by health care providers to provide better treatments for pain have consequently caused a rise in misuse, abuse, addiction, and diversion of many prescription opioids.[@b2-sar-2-219] A prime example of the misuse and abuse of prescription opioids occurred in the state of Florida, where the death rate for prescription drugs increased approximately 84%, from 7.3 to 13.4 per 100,000 of the population from 2003 to 2009, with the greatest increase for prescription oxycodone (264.6%), methadone (79.2%), hydrocodone (34.9%), and morphine (26.2%).[@b3-sar-2-219] Since the effects of opioid abuse can go beyond the individual and cause multiple social, economic, and health problems,[@b4-sar-2-219]--[@b6-sar-2-219] effective treatment options are critical for both the illicit drug and prescription opioid abuser.

Management of opioid abuse
--------------------------

Opioid abuse can be a lifelong battle that requires substantial resources and therapeutic efforts by the patient, health care providers, regulatory agencies, and others. Additionally, opioid abusers come from different backgrounds and have different motivations and intentions when it comes to abuse. In an effort to accommodate the entire spectrum of opioid abusers, different prevention methods have been employed by physicians, regulatory bodies, and pharmaceutical companies. In an effort to counter potential short-term abuse, newer formulations of opioid agonists have come onto the market in order to make the product more tamper resistant and/or less desirable or appealing to abusers.[@b7-sar-2-219]--[@b9-sar-2-219] Many extended-release formulations (eg, Remoxy®, King Pharmaceuticals, Inc, Cary, NC; Acuracet®, Acura Pharmaceuticals, Inc, Palatine, IL; Exalgo®, Mallinckrodt Inc, Hazelwood, MO) in addition to tamper-resistant (eg, Embeda®, Alpharma Pharmaceuticals LLC, Bridgewater, NJ) and dependence-deterrent formulations (Oxytrex®, Pain Therapeutics, Inc, San Francisco, CA; Suboxone®, Reckitt Benckiser Pharmaceuticals Inc, Richmond, VA) of agonist-antagonist combinations have been designed as abuse barriers. However, these formulations provide little benefit to the opioid-dependent patients looking to quit long-term abuse and thus these patients require other methods of treatment. Current therapies for opioid-dependent patients include (1) an agonist-based approach such as methadone, buprenorphine, or a buprenorphine-naloxone combination; (2) an antagonist-based approach, which includes the daily administration of the opioid antagonist naltrexone; or (3) a pharmacological approach combined with psychotherapy and patient supervision. The choice of approach is usually based on patient and physician preference along with the patient's past medical and treatment history and even their financial status.[@b10-sar-2-219]--[@b14-sar-2-219]

### Agonist-based approach

In its simplest form, agonist therapy is a supervised administration of a long-acting opioid receptor agonist with the goal to reduce or eliminate illicit drug use, increase retention in treatment, and help reduce many of the risk factors associated with illicit drug use (crime, infections, and so forth).[@b15-sar-2-219],[@b16-sar-2-219] Current therapies for opioid dependence may consist of methadone (Dolophine®, Roxane Laboratories, Inc, Columbus, OH; Methadose®, Mallinckrodt Specialty Chemicals Company, St Louis, MO), buprenorphine (Subutex® and Suboxone, Reckitt Benckiser Pharmaceuticals Inc), and the less frequently used levomethadyl acetate.[@b17-sar-2-219] Methadone treatment was the first treatment to become available (in the 1960s), followed by the use of buprenorphine in doctors' offices around the year 2000. Guidelines put forth by the World Federation of Societies of Biological Psychiatry,[@b16-sar-2-219] two Cochrane reviews,[@b18-sar-2-219],[@b19-sar-2-219] and the World Health Organization[@b20-sar-2-219] have concluded that there is an excellent evidence base supporting the efficacy of both methadone and buprenorphine for the treatment of opioid withdrawal and maintenance. Despite evidence of efficacy of agonist therapies, many countries and some US states have made agonist therapies unavailable or have severely restricted their access.[@b21-sar-2-219] Even when therapies are available, not all patients are eligible or accepted for such treatment, owing to long waiting lists, lack of money or health insurance, or failure to produce a photo identification card on request.[@b22-sar-2-219],[@b23-sar-2-219] Furthermore, not all treatment providers or patients agree on this method of therapy, especially in patients who are young, have short dependence histories, or just do not want to take part in a lengthy detoxification therapy.[@b23-sar-2-219] In addition, some practitioners are concerned about the side effects associated with long-term use of these opioids (eg, hypogonadism or immune suppression).[@b24-sar-2-219],[@b25-sar-2-219] Even though the agonist approach is effective, the limitations and concerns associated with this therapy have created a need for introducing effective antagonist treatments.

### Antagonist-based approach

Opioid-dependent patients may be placed on an antagonist therapy. Opioid receptor antagonists block the effects generated by opioid agonists without producing any agonist effects of their own ([Figure 1](#f1-sar-2-219){ref-type="fig"}). Thus, they have no abuse liability, no overdose potential, and they do not require special waivers to be prescribed.[@b26-sar-2-219]--[@b28-sar-2-219] Currently, naltrexone (Depade®, Mallinckrodt Specialty Chemicals Company; Revia®, Bristol-Myers Squibb Pharma Company, Princeton, NJ) is a recommended opioid antagonist both for opioid withdrawal and for maintenance. Naltrexone therapy may be useful in preventing relapse in patients who have withdrawn from opioids and/or those motivated enough to abstain from opioid use.[@b20-sar-2-219] However, the effectiveness of the antagonist-based approach has been somewhat disappointing and there is insufficient evidence to unequivocally support the clinical effectiveness of oral naltrexone in the treatment of opioid dependence.[@b29-sar-2-219],[@b30-sar-2-219] Its ineffectiveness can largely be traced to lack of patient adherence and retention. Thus, oral naltrexone has become a therapy mainly for the highly motivated individual.

### Pharmacological approach in combination with psychosocial therapy

In an effort to increase therapy retention rates, increase reduction in illicit opioid use, and help improve patients' quality of life, the concurrent use of psychosocial interventions has been recommended for both agonist and antagonist therapies.[@b20-sar-2-219] Psychosocial interventions may include cognitive and behavioral approaches, as well as contingency management techniques. A recent systematic review of the literature identified 28 randomly controlled trials that address the advantage of combining psychosocial therapy with agonist maintenance treatments.[@b31-sar-2-219]

When a comparison was made between psychosocial plus maintenance pharmacological treatment and standard maintenance treatment, the results did not indicate any benefit in retention rate (relative risk \[RR\]: 1.02; 95% confidence interval \[CI\]: 0.97, 1.07), opiate use during the treatment (RR: 0.86; 95% CI: 0.65, 1.13), compliance (mean difference \[MD\]: 0.43; 95% CI: −0.05, 0.92), psychiatric symptoms (MD: 0.02; 95% CI: −0.19, 0.23), depression (MD: −1.30; 95% CI: −3.31, 0.72), or number of participants still in treatment at the end of the follow-up (RR: 0.91; 95% CI: 0.77, 1.06). However, the number of participants abstinent at the end of the follow-up showed a benefit in favor of the associated treatment (RR: 1.15; 95% CI: 1.01, 1.32).[@b31-sar-2-219] In addition, psychosocial programs in combination with antagonist treatment have demonstrated effectiveness in maintaining abstinence and retention.[@b32-sar-2-219],[@b33-sar-2-219] For example, in a study with 127 detoxified opioid-dependent patients, patients utilizing both naltrexone treatment and a contingency program versus naltrexone alone showed both treatment retention (7.4 vs 5.6 weeks; *P* = 0.05) and reduction of opioid use (19 vs 14 opioid-free urine samples; *P* = 0.04).[@b32-sar-2-219]

Each of the approaches described here has its advantages and its disadvantages; however, underutilization of agonist therapies, unavailability of treatments, and inadequate success rates have created a need for other approaches. The focus of the present review is the current information regarding the safety and efficacy of naltrexone extended-release therapy.

Methods
=======

The search strategy for the identification of studies included the electronic searching of the PubMed/MEDLINE database, Embase, and The Cochrane Library from database inception through to July 2011. Search terms used individually or in combination included "naltrexone," "extended release naltrexone," "injectable naltrexone," "opioid antagonist," and "opioid dependence." The identified citations were then further limited to any clinical study or review article describing clinical use of injectable extended-release naltrexone. The goal was to present the reader with all published studies regardless of their design type. Studies exclusively describing other forms of naltrexone, including oral or implantable naltrexone, were eliminated. To identify any articles missed by the electronic search, the bibliographies of the electronically identified articles were analyzed and any appropriate articles, based on title and abstract, were retrieved.

Discussion
==========

New formulations
----------------

### Antagonist approach

Physicians originally had high hopes for antagonist therapies due to the pharmacological profile of these agents in the laboratory. However, clinicians soon realized that the effectiveness of the antagonists in the laboratory could not always be duplicated so readily in the clinic. Because the antagonist approach relies so heavily on a motivated and conscientious individual to maintain good compliance, a requirement of multiple oral dosing can represent a significant impediment to achieving successful treatment. In an effort to abrogate the problem of patient noncompliance with oral dosing, extended-release, injectable (depot) formulations of the antagonist naltrexone have been developed by three companies. Such an approach would seem to be a desirable method for delivering an opioid antagonist to opioid-dependent patients.[@b34-sar-2-219]

### Extended-release naltrexone formulations

Currently there are three depot injection formulations available for extended-release naltrexone treatment, each providing therapeutic blood levels for approximately 4 weeks. There are two that have not yet been approved by the US Food and Drug Administration (FDA): Depotrex® (Biotek Inc, Woburn, MA) and Naltrel® (DrugAbuse Sciences SAS, Paris, France). Vivitrol® (Alkermes, Waltham, MA) was originally approved for alcohol dependence and received FDA approval for opioid dependence in late 2010. In addition to these depot extended-release injection formulations, biodegradable polylactic acid-based polymer naltrexone implant formulations are currently under investigation.[@b35-sar-2-219]--[@b38-sar-2-219] The clinical safety and efficacy of these implants are beyond the scope of this review; rather, focus will be on the extended-release injection formulation.

Extended-release naltrexone: efficacy studies
---------------------------------------------

Comer et al[@b39-sar-2-219] examined the safety and efficacy of 192 mg (n = 6) and 384 mg (n = 6) doses of a sustained-release naltrexone (Depotrex) on twelve heroin-dependent patients in an 8-week inpatient study. After a 1-week detoxification period, participants were treated with either dose of naltrexone, followed by 6 weeks of challenge with heroin (0, 6.25, 12.5, 18.75, 25 mg, intravenously). Various subjective, performance, and physiological effects were measured before and after the heroin administration. Both doses of sustained-release naltrexone antagonized the heroin-induced subjective, performance, and physiological effects; the 192 mg dose did so for up to 3 weeks, and the 384 mg dose for up to 5 weeks. In addition, participants did not experience any major side effects except discomfort associated with the initial injection of the naltrexone. These initial results seemed promising for a new treatment therapy.

In a second study, Comer et al[@b40-sar-2-219] conducted a double-blind, 8-week randomized trial on 60 heroin addicts. During weeks 1 and 5, participants received a single injection of placebo or extended-release naltrexone (Depotrex; either 192 mg or 384 mg) in addition to biweekly preventive therapy sessions. The main outcome measures included retention of treatment and percentage of opioid-negative urine samples. At the end of 8 weeks, 39% (7/18) of those treated with placebo, 60% (12/20) of those treated with naltrexone 192 mg, and 68% (15/22) of those treated with naltrexone 384 mg remained in the treatment. There were also statistically significant differences (*P* \< 0.002) in mean dropout time in the placebo group (27 days), the naltrexone 192 mg group (36 days), and the naltrexone 384 mg group (48 days). When urine samples were tested for traces of opioids, differences were noted between the placebo (25.3%) and naltrexone 192 mg (47.1%) groups and between the placebo and naltrexone 384 mg (61.9%) groups; however, when adjusted for missed visits or samples, the differences were not statistically significant (*P* = 0.85). Although patients in the naltrexone groups reported "needing heroin less," there was no difference in those "wanting heroin." Similar to the previous study, side effects included induration (hardness) and pain at the injection site.

Brooks et al[@b41-sar-2-219] utilized a quasi-experimental uncontrolled design to analyze and compare extended-release and oral naltrexone. At the time there was no study with a head-to-head comparison of investigative depot formulations and approved oral naltrexone. In this study, Brooks et al analyzed treatment retention and opioid use in heroin-dependent patients during an 8-week period where patients were treated with either long-acting injectable naltrexone or oral naltrexone with psychosocial intervention. In Comer et al's[@b40-sar-2-219] injectable naltrexone study already described, patients receiving injectable naltrexone (n = 42) remained on the treatment longer than patients on oral naltexone (n = 69) (42.3 vs 31.9 days; *P* = 0.012) after 8 weeks. During the 8 weeks of detoxification, injectable naltrexone patients had a similar level of negative urine tests to those in the oral naltrexone group (55% vs 50%). However, when missing urine samples were considered positive, injectable naltrexone patients had statistically fewer positive urine tests than the oral naltrexone patients (*P* = 0.024). No patient in these studies was seen to attempt overriding naltrexone. Even though the results of this study point to extended-release naltrexone as superior to oral naltrexone, the analytical approach should be considered exploratory; a true comparative trial is lacking.

Krupitsky et al[@b42-sar-2-219] assessed the efficacy and safety of extended-release injectable naltrexone 380 mg (Vivitrol) in 250 opioid-dependent patients. The primary end points were urine drug tests and self-reporting of abstinence during weeks 5--24. Secondary end points consisted of self-reported opioid-free days, opioid-craving scores, number of days of retention, and relapse. During weeks 5--24, a median of 90% were confirmed abstinent weeks (by urine analysis) in the treatment group, compared with 35% in the placebo group (*P* = 0.0002). Those in the treatment group self-reported a median of 99% opioid-free days, compared with 60% reported by the placebo group. In addition, there were statistically significant differences (*P* \< 0.0001) between the naltrexone and the placebo groups in craving reduction (mean score = −10.1 vs 0.7, respectively) and retention (median = 168 vs 96 days, respectively; *P* = 0.0042). During the 24-week study, more participants in the naltrexone group experienced one or more adverse events (including nasopharyngitis, insomnia, hypertension, influenza, pain at the injection site, toothache, and headache) than in the placebo group. There were no overdose events, suicide attempts, or deaths reported.

A retrospective study by Fishman et al[@b43-sar-2-219] analyzed an open-label case series to assess acceptability, feasibility, and preliminary outcomes in opioid-dependent adolescents and young adults (average age 18.5 years) using extended-release naltrexone (Vivitrol) once every 4 weeks. Primary end points consisted of number of doses received after a 4-month treatment period and reduction in illicit opioid use. Sixteen of the 19 patients analyzed returned for at least one outpatient follow-up after receiving extended-release naltrexone. Of these sixteen patients, two (12.5%) dropped out after one follow-up session and ten (63%) remained in treatment for 4 months. The mean number of doses of nal-trexone received during the 4 months after initiation was 2.5 (median 3), with twelve patients (75%) receiving at least two doses. Seven patients (44%) continued naltrexone beyond 4 months, eleven (69%) were abstinent or had significant reductions in opioid use, and nine (56%) met the criteria for a "good" outcome at 4 months. In terms of safety, the only side effect examined was reports of overdose, of which none were documented.

In order to determine if extended-release naltrexone plus employment-based reinforcement can foster longer-term adherence, DeFulio et al[@b44-sar-2-219] conducted a randomized trial of unemployed heroin-dependent patients (N = 38). Participants were given either extended-release naltrexone (Vivitrol) (n = 19) or the same plus a contingency program (n = 19) for 24 weeks. The contingency program consisted of a therapeutic workplace where participants could earn vouchers for attendance and participation in training programs. To stay within the program, they were required to receive naltrexone injections at 4-week intervals, but they could earn vouchers independent of their acceptance of naltrexone. Those in the employment-based contingency group accepted significantly more naltrexone injections than those in the naltrexone-only group (87% vs 52%; *P* = 0.002) and were more likely to accept the total of six injections (74% vs 26%; *P* = 0.004). However, there was no statistical difference between groups for opiate-negative (72% vs 65%; *P* = 0.56) or cocaine-negative (58% vs 54%; *P* = 0.75) urine samples.

Using the same experimental protocol, Everly et al[@b45-sar-2-219] tested the adherence rate to extended-release naltrexone (Depotrex) in conjugation with an employment-based contingency program. Similar to the results of the previous study, the group that received both naltrexone and an employment-based reinforcement accepted significantly more naltrexone injections than the naltrexone-only group (81% vs 42%; *P* = 0.008) over the 24-week study, and they were more likely to accept all of the injections (66% vs 35%). However, both groups had similar numbers of opiate-negative (74% vs 62%; *P* = 0.413) or cocaine-negative (56% vs 54%; *P* = 0.939) urine samples.

Extended-release naltrexone: safety studies
-------------------------------------------

In the clinical studies summarized, the acute side effects reported following administration of extended-release injectable naltrexone were mainly the same as those observed following oral administration of naltrexone. They included nausea, vomiting, decreased appetite, somnolence, fatigue, headache, dizziness, and anxiety. Systematic reviews of the effectiveness and safety of sustained-release naltrexone for opioid dependence[@b46-sar-2-219],[@b47-sar-2-219] concluded that adverse events of extended-release naltrexone were similar to that of oral naltrex-one, but these events were more prominent in the naltrexone groups than in the placebo groups. Several of the studies documented irritation, induration, and pain at the site of injection. These adverse effects were not seen in the placebo groups and thus warnings are currently on the label of Vivitrol.[@b47-sar-2-219]

A potential risk that may be unique to extended-release formulations of naltrexone is the possibility that patients may attempt to remove the medication from within the site of injection. However, to the authors' knowledge, no documented cases have appeared in the literature. Other potential side effects may include impairment in liver function and sexual dysfunction. Some early studies using oral formulations of naltrexone have suggested that naltrexone may produce hepatotoxicity and thus current warnings are listed on the prescription label of Vivitrol.[@b48-sar-2-219],[@b49-sar-2-219] Other data have disputed this,[@b50-sar-2-219] but it is still a boxed warning. There has been no conclusive evidence reported of liver damage in patients receiving the recommended dosages of naltrexone.[@b51-sar-2-219],[@b52-sar-2-219] A report warned of sexual dysfunction with long-term oral naltrexone use, but confirmatory investigation is needed since prior long-term opioid agonist use may have led to the sexual dysfunction.[@b53-sar-2-219]

### Opioid overdose

A concern raised about extended-release naltrexone is opioid agonist overdose. It is cautioned that this may occur in two ways, the first at accustomed doses of opioid agonist due to unanticipated opioid receptor "sensitization" during extended antagonist exposure and the second at unaccustomed high doses of opioid agonist during an intentional attempt to "override" the receptor antagonism. It is well known that in many model systems extended exposure to opioid antagonists can upregulate opioid receptors and increase their density throughout the central nervous system.[@b54-sar-2-219]--[@b59-sar-2-219] These changes can result in functional supersensitivity,[@b60-sar-2-219],[@b61-sar-2-219] and an accidental "overdose" may occur even if agonist dose is not increased and antagonist treatment has been discontinued.

An abuser may attempt to override naltrexone's receptor blockade with higher doses of opioid agonists, or by taking opioids at the end of naltrexone's dosing interval, a time when plasma levels are decreasing and the blockade is diminishing.[@b49-sar-2-219],[@b62-sar-2-219] None of the studies presented in this review indicated any overdose cases, but there have been reports of opioid overdose in patients after discontinuation of oral naltrexone maintenance.[@b63-sar-2-219],[@b64-sar-2-219] To further investigate these overdose scenarios, future studies may look to increase follow-up assessments and treatment periods.

### Antagonism of pain medication

Patients who are on extended-release naltrexone have diminished capacity to experience the analgesic effects of opioid agonists. Pain management may become a challenge because analgesia will not be possible with administration of opioids. Patient cases have been reported where successful analgesia was achieved using nonopioid analgesics or a local anesthetic technique.[@b65-sar-2-219]

Conclusion
==========

Systematic reviews support the safety and efficacy of the "agonist approach" (mainly methadone and buprenorphine), albeit with long-term success rates having been a matter of debate.[@b66-sar-2-219]--[@b73-sar-2-219] Less evidence supports the utility of the "antagonist approach" (mainly naltrexone), despite the fact that the approach is seemingly so logical (reduced receptor access to an agonist should attenuate agonist-induced rewarding effects). Part of the problem is that a high level of motivation and compliance is necessary.

Naltrexone initially was available only in an oral formulation. A once-monthly injectable (depot) form was developed in order to improve the chances of compliance. The FDA approved Vivitrol in October 2010 for prevention of relapse to opioid dependence following opioid detoxification, to be used along with concurrent counseling and social support. Approval was based mainly on a single study and this has generated some criticism of the process. However, the safety and effectiveness of Vivitrol will now be validated, or not, in clinical use. To the authors' knowledge, no controlled studies directly compare the safety and efficacy of the extended-release formulation and the oral formulation, or methadone or buprenorphine maintenance treatment.

Oral naltrexone carries a warning for hepatocellular injury when given in excessive doses and it is contraindicated in acute hepatitis or liver failure; its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects. Vivitrol does not appear to be a hepatotoxin at the recommended doses, but the margin of separation between the apparently safe dose and the dose causing hepatic injury is stated to be only fivefold or less.

Given the important medical and societal needs for treatment of opioid abuse and the absence of a current 100% effective treatment, an extended-release opioid antagonist (naltrexone) appears to offer the hope of overcoming the compliance issues of oral naltrexone. Switching from a once-daily (oral) to a once-monthly (injectable) schedule of administration may also provide a psychological advantage, uncoupling drug taking from rewarding effect. Current research does not provide sufficient evidence to make conclusions about the effectiveness or safety of injectable naltrexone in the management of opioid dependence; further research is needed to put this question to rest.
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![Mechanism of action of naltrexone. The reversible interaction of an opioid agonist with opioid receptors, which are part of the seven-transmembrane, G-protein-coupled receptor family, elicits opioid-induced effects, including those desired by abusers. Opioid receptor antagonists such as naltrexone also reversibly bind to opioid receptors, but they lack intrinsic activity and thus do not elicit an opioid-like effect. However, their binding limits the number of unoccupied receptors and, consequently, the magnitude of agonist-induced opioid effects. Naltrexone, 17-(cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, is a substituted oxymorphone (the tertiary amine methyl group is replaced with methylcyclopropane) and the *N*-cyclopropylmethyl derivative of oxymorphone. Naltrexone's major metabolite, 6-β-naltrexone, is also a competitive antagonist at opioid receptors.\
**Abbreviations:** ATP, adenosine triphosphate; cAmp, cyclic adenosine monophosphate; GDP, guanosine diphosphate; GTP, guanosine triphosphate.](sar-2-219Fig1){#f1-sar-2-219}
